Sarepta Therapeutics, Inc. (SRPT) stock
SRPTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/3085% below fair value
$16.07+0.06 (+0.37%)
Close on Nov 13, 2026Market cap $1.70BP/E –Yield –
Sarepta Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
Sarepta Therapeutics's gross margin for the twelve months ending Dec 31, 2025 was 98.8%. For fiscal 2025 it was 98.8%, against 97.6% the year before.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 98.8% | +1.2 |
| FY2016 | Dec 31, 2016 | 97.6% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -6.6% | −83.4 |
| Q3 FY2025 | Sep 30, 2025 | 54.9% | −17.5 |
| Q2 FY2025 | Jun 30, 2025 | 59.0% | −28.1 |
| Q1 FY2025 | Mar 31, 2025 | 63.6% | −11.1 |
| Q4 FY2024 | Dec 31, 2024 | 76.8% | −21.6 |
| Q3 FY2024 | Sep 30, 2024 | 72.4% | −26.1 |
| Q2 FY2024 | Jun 30, 2024 | 87.1% | −10.5 |
| Q1 FY2024 | Mar 31, 2024 | 74.7% | – |
| Q2 FY2017 | Jun 30, 2017 | 98.5% | – |
| Q1 FY2017 | Mar 31, 2017 | 98.5% | – |
| Q4 FY2016 | Dec 31, 2016 | 97.6% | – |
See a number that looks wrong?